Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL

S. Pavlova, J. Malcikova, L. Radova, S. Bonfiglio, JB. Cowland, C. Brieghel, MK. Andersen, M. Karypidou, B. Biderman, M. Doubek, G. Lazarian, I. Rapado, M. Vynck, NA. Porret, M. Andres, D. Rosenberg, D. Sahar, C. Martínez-Laperche, I. Buño, A....

. 2025 ; 9 (1) : e70065. [pub] 20250120

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008611

In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using their NGS method of choice. The sensitivity was 85.6%, 94.5%, and 94.8% at 1%, 2%, and 3% VAF cut-off, respectively. While only one false positive (FP) result was reported at >2% VAF, it was more challenging to distinguish true variants <2% VAF from background noise (37 FPs reported by 9 laboratories). The impact of low-VAF variants on time-to-second-treatment (TTST) and overall survival (OS) was investigated in a series of 1092 patients. Among patients not treated with targeted agents, patients with low-VAF TP53 variants had shorter TTST and OS versus wt-TP53 patients, and the relative risk of second-line treatment or death increased continuously with increasing VAF. Targeted therapy in ≥2 line diminished the difference in OS between patients with low-VAF TP53 variants and wt-TP53 patients, while patients with high-VAF TP53 variants had inferior OS compared to wild type-TP53 cases. Altogether, NGS-based approaches are technically capable of detecting low-VAF variants. No strict threshold can be suggested from a technical standpoint, laboratories reporting TP53 mutations should participate in a standardized validation set-up. Finally, whereas low-VAF variants affected outcomes in patients receiving chemoimmunotherapy, their impact on those treated with novel therapies remains undetermined. Our results pave the way for the harmonized and accurate TP53 assessment, which is indispensable for elucidating the role of TP53 mutations in targeted treatment.

AgenDix GmbH Dresden Germany

B Cell Neoplasia Unit and Strategic Research Program on CLL IRCCS Ospedale San Raffaele Milan Italy

Cancer Molecular Diagnostics Department Centre for Laboratory Medicine and Molecular Pathology St James Hospital Dublin Ireland

Center for Omics Sciences IRCCS Ospedale San Raffaele Milan Italy

Central Diagnostic Laboratory University Medical Center Utrecht Utrecht The Netherlands

Centre for Molecular Medicine Central European Institute of Technology Masaryk University Brno Czech Republic

Departement d'Hematologie et Immunologie Biologique AP HP Hopital Henri Mondor Creteil France

Department of Biological Hematology Sorbonne Université AP HP Pitié Salpêtrière Hospital Paris France

Department of Cell Biology Medical School Complutense University of Madrid Madrid Spain

Department of Clinical Genetics and Genomics Karolinska University Hospital Stockholm Sweden

Department of Clinical Genetics Centre of Diagnostic Investigations Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Department of Hematological Diagnostics and Genetics University Hospital in Krakow Krakow Poland

Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital University of Bern Bern Switzerland

Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Department of Hematology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands

Department of Hematology Gregorio Marañón General University Hospital Gregorio Marañón Health Research Institute Madrid Spain

Department of Hematology Hospital Universitari Vall d'Hebron Barcelona Spain

Department of Hematology Hospital Universitario 12 de Octubre Instituto de Investigación Sanitaria Hospital 12 de Octubre Complutense University CNIO CIBERONC Madrid Spain

Department of Hematology University Hospital of Salamanca Salamanca Spain

Department of Human Anatomy and Histology Faculty of Medicine University of Salamanca Salamanca Spain

Department of Immunology Genetics and Pathology Uppsala University Uppsala Sweden

Department of Internal Medicine 3 Ulm University Ulm Germany

Department of Internal Medicine Hematology and Oncology and Institute of Medical Genetics and Genomics University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic

Department of Laboratory Genetics Genetics and Personalized Clinic Tartu University Hospital Tartu Estonia

Department of Laboratory Medicine AZ Sint Jan Hospital Bruges Belgium

Department of Medicine Universitat Autònoma de Barcelona Barcelona Spain

Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden

Department of Tumor Biology and Genetics Medical University of Warsaw Warsaw Poland

Experimental Hematology Vall d'Hebron Institute of Oncology Barcelona Spain

Genetics and Personalized Medicine Clinic Institute of Clinical Medicine Tartu University Tartu Estonia

Genomed Diagnósticos de Medicina Molecular iMM Instituto de Medicina Molecular Faculdade de Medicina Lisboa Portugal

Genomics Unit Gregorio Marañón General University Hospital Gregorio Marañón Health Research Institute Madrid Spain

Haematology Department Belfast City Hospital Belfast UK

Hematology Department Hospital Clínico Universitario INCLIVA Valencia Spain

Hematology Department Hospital Universitari i Politècnic la Fe Valencia Spain

Hematology laboratory HUPSSD Hôpital Avicenne APHP Bobigny France

Hematology Laboratory Rambam Medical Center Haifa Israel

INSERM U978 Université Sorbonne Paris Nord Bobigny France

Institut Universitaire de Cancérologie de Toulouse Toulouse France

Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece

Institute of Oncology Research and Oncology Institute of Southern Switzerland Bellinzona Switzerland

Laboratoire d'Hématologie Biologique CHU Bordeaux Bordeaux France

Laboratorio di Diagnostica Molecolare Servizio di Genetica Medica EOLAB Ente Ospedaliero Cantonale Bellinzona Switzerland

Laboratório Hemato Oncologia Instituto Português de Oncologia de Lisboa Lisbon Portugal

Laboratorio specialistico UOC ematologia Ospedale San Francesco ASL Nuoro Italy

Medical School Università Vita Salute San Raffaele Milan Italy

Molecular Cytogenetics Unit Hematology Department Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain

Molecular Pathology University Hospitals Dorset Bournemouth UK

National Medical Research Center for Hematology Moscow Russia

Oncohematology Research Group Institute of Biomedical Research of Salamanca and University of Salamanca Salamanca Spain

Outpatient department of Hematology Oncology and Chemotherapy Botkin Hospital and Department of Hematology and Transfusiology Russian Medical Academy of Continuous Professional Education Moscow Russia

Pathology Department Hospital del Mar IMIM Barcelona Spain

Servicio de Hematología Hospital Universitario de Gran Canaria Dr Negrín Departamento de Morfología de La Universidad de Las Palmas de Gran Canaria Gran Canaria Spain

Serviço de Hematologia Instituto Português de Oncologia de Lisboa Lisbon Portugal

Univ Paris Est Creteil INSERM IMRB Creteil France

UOC Hematology Mazzoni Hospital Ascoli Piceno Ascoli Piceno Italy

Wessex Genomics Laboratory Service Salisbury NHS Foundation Trust Salisbury UK

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008611
003      
CZ-PrNML
005      
20250422095736.0
007      
ta
008      
250408s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hem3.70065 $2 doi
035    __
$a (PubMed)39840379
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pavlova, Sarka $u Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic $u Centre for Molecular Medicine, Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic $1 https://orcid.org/0000000315289743
245    10
$a Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL / $c S. Pavlova, J. Malcikova, L. Radova, S. Bonfiglio, JB. Cowland, C. Brieghel, MK. Andersen, M. Karypidou, B. Biderman, M. Doubek, G. Lazarian, I. Rapado, M. Vynck, NA. Porret, M. Andres, D. Rosenberg, D. Sahar, C. Martínez-Laperche, I. Buño, A. Hindley, D. Donaldson, JB. Sánchez, JA. García-Marco, A. Serrano-Alcalá, B. Ferrer-Lores, C. Fernández-Rodriguez, B. Bellosillo, S. Stilgenbauer, E. Tausch, H. Nikdin, F. Quinn, E. Atkinson, L. van de Corput, C. Yildiz, C. Bilbao-Sieyro, Y. Florido, C. Thiede, C. Schuster, A. Stoj, S. Czekalska, A. Chatzidimitriou, S. Laidou, A. Bidet, C. Dussiau, F. Nollet, G. Piras, M. Monne, S. Smirnova, E. Nikitin, I. Sloma, A. Claudel, L. Largeaud, L. Ysebaert, PJM. Valk, A. Christian, R. Walewska, D. Oscier, M. Sebastião, MG. da Silva, P. Galieni, M. Angelini, D. Rossi, V. Spina, S. Matos, V. Martins, T. Stokłosa, M. Pepek, P. Baliakas, R. Andreu, I. Luna, T. Kahre, Ü. Murumets, T. Pikousova, T. Kurucova, S. Laird, D. Ward, M. Alcoceba, A. Balanzategui, L. Scarfo, F. Gandini, E. Zapparoli, A. Blanco, P. Abrisqueta, AE. Rodríguez-Vicente, R. Benito, C. Bravetti, F. Davi, P. Gameiro, J. Martinez-Lopez, B. Tazón-Vega, F. Baran-Marszak, Z. Davis, M. Catherwood, A. Sudarikov, R. Rosenquist, CU. Niemann, K. Stamatopoulos, P. Ghia, S. Pospisilova
520    9_
$a In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using their NGS method of choice. The sensitivity was 85.6%, 94.5%, and 94.8% at 1%, 2%, and 3% VAF cut-off, respectively. While only one false positive (FP) result was reported at >2% VAF, it was more challenging to distinguish true variants <2% VAF from background noise (37 FPs reported by 9 laboratories). The impact of low-VAF variants on time-to-second-treatment (TTST) and overall survival (OS) was investigated in a series of 1092 patients. Among patients not treated with targeted agents, patients with low-VAF TP53 variants had shorter TTST and OS versus wt-TP53 patients, and the relative risk of second-line treatment or death increased continuously with increasing VAF. Targeted therapy in ≥2 line diminished the difference in OS between patients with low-VAF TP53 variants and wt-TP53 patients, while patients with high-VAF TP53 variants had inferior OS compared to wild type-TP53 cases. Altogether, NGS-based approaches are technically capable of detecting low-VAF variants. No strict threshold can be suggested from a technical standpoint, laboratories reporting TP53 mutations should participate in a standardized validation set-up. Finally, whereas low-VAF variants affected outcomes in patients receiving chemoimmunotherapy, their impact on those treated with novel therapies remains undetermined. Our results pave the way for the harmonized and accurate TP53 assessment, which is indispensable for elucidating the role of TP53 mutations in targeted treatment.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Malcikova, Jitka $u Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic $u Centre for Molecular Medicine, Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic $1 https://orcid.org/0000000336506698
700    1_
$a Radova, Lenka $u Centre for Molecular Medicine, Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic $1 https://orcid.org/000000018103148X
700    1_
$a Bonfiglio, Silvia $u B-Cell Neoplasia Unit and Strategic Research Program on CLL IRCCS Ospedale San Raffaele Milan Italy $u Center for Omics Sciences IRCCS Ospedale San Raffaele Milan Italy
700    1_
$a Cowland, Jack B $u Department of Clinical Genetics, Centre of Diagnostic Investigations Copenhagen University Hospital - Rigshospitalet Copenhagen Denmark
700    1_
$a Brieghel, Christian $u Department of Hematology Copenhagen University Hospital - Rigshospitalet Copenhagen Denmark
700    1_
$a Andersen, Mette K $u Department of Clinical Genetics, Centre of Diagnostic Investigations Copenhagen University Hospital - Rigshospitalet Copenhagen Denmark
700    1_
$a Karypidou, Maria $u Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
700    1_
$a Biderman, Bella $u National Medical Research Center for Hematology Moscow Russia $1 https://orcid.org/0000000262533334
700    1_
$a Doubek, Michael $u Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic $u Centre for Molecular Medicine, Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic $1 https://orcid.org/0000000212696282
700    1_
$a Lazarian, Gregory $u Hematology laboratory HUPSSD, Hôpital Avicenne, APHP Bobigny France $u INSERM U978 Université Sorbonne Paris Nord Bobigny France $1 https://orcid.org/0000000243153440
700    1_
$a Rapado, Inmaculada $u Department of Hematology Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Complutense University, CNIO, CIBERONC Madrid Spain
700    1_
$a Vynck, Matthijs $u Department of Laboratory Medicine AZ Sint-Jan Hospital Bruges Belgium $1 https://orcid.org/000000019875385X
700    1_
$a Porret, Naomi A $u Department of Hematology and Central Hematology Laboratory, Inselspital Bern University Hospital, University of Bern Bern Switzerland $1 https://orcid.org/0000000225151935
700    1_
$a Andres, Martin $u Department of Hematology and Central Hematology Laboratory, Inselspital Bern University Hospital, University of Bern Bern Switzerland $1 https://orcid.org/0000000198912988
700    1_
$a Rosenberg, Dina $u Hematology Laboratory Rambam Medical Center Haifa Israel
700    1_
$a Sahar, Dvora $u Hematology Laboratory Rambam Medical Center Haifa Israel
700    1_
$a Martínez-Laperche, Carolina $u Department of Hematology Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM) Madrid Spain
700    1_
$a Buño, Ismael $u Department of Hematology Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM) Madrid Spain $u Genomics Unit Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM) Madrid Spain $u Department of Cell Biology, Medical School Complutense University of Madrid Madrid Spain
700    1_
$a Hindley, Andrew $u Haematology Department Belfast City Hospital Belfast UK
700    1_
$a Donaldson, David $u Haematology Department Belfast City Hospital Belfast UK
700    1_
$a Sánchez, Julio B $u Molecular Cytogenetics Unit, Hematology Department Hospital Universitario Puerta de Hierro-Majadahonda Madrid Spain
700    1_
$a García-Marco, José A $u Molecular Cytogenetics Unit, Hematology Department Hospital Universitario Puerta de Hierro-Majadahonda Madrid Spain
700    1_
$a Serrano-Alcalá, Alicia $u Hematology Department Hospital Clínico Universitario-INCLIVA Valencia Spain $1 https://orcid.org/0000000233924336
700    1_
$a Ferrer-Lores, Blanca $u Hematology Department Hospital Clínico Universitario-INCLIVA Valencia Spain
700    1_
$a Fernández-Rodriguez, Concepción $u Pathology Department Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain $1 https://orcid.org/0000000258530843
700    1_
$a Bellosillo, Beatriz $u Pathology Department Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
700    1_
$a Stilgenbauer, Stephan $u Department of Internal Medicine III Ulm University Ulm Germany
700    1_
$a Tausch, Eugen $u Department of Internal Medicine III Ulm University Ulm Germany
700    1_
$a Nikdin, Hero $u Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden $u Department of Clinical Genetics and Genomics Karolinska University Hospital Stockholm Sweden
700    1_
$a Quinn, Fiona $u Cancer Molecular Diagnostics Department Centre for Laboratory Medicine and Molecular Pathology, St. James Hospital Dublin Ireland
700    1_
$a Atkinson, Emer $u Cancer Molecular Diagnostics Department Centre for Laboratory Medicine and Molecular Pathology, St. James Hospital Dublin Ireland
700    1_
$a van de Corput, Lisette $u Central Diagnostic Laboratory University Medical Center Utrecht Utrecht The Netherlands
700    1_
$a Yildiz, Cafer $u Central Diagnostic Laboratory University Medical Center Utrecht Utrecht The Netherlands
700    1_
$a Bilbao-Sieyro, Cristina $u Servicio de Hematología Hospital Universitario de Gran Canaria Dr. Negrín, Departamento de Morfología de La Universidad de Las Palmas de Gran Canaria Gran Canaria Spain
700    1_
$a Florido, Yanira $u Servicio de Hematología Hospital Universitario de Gran Canaria Dr. Negrín, Departamento de Morfología de La Universidad de Las Palmas de Gran Canaria Gran Canaria Spain
700    1_
$a Thiede, Christian $u AgenDix GmbH Dresden Germany
700    1_
$a Schuster, Caroline $u AgenDix GmbH Dresden Germany
700    1_
$a Stoj, Anastazja $u Department of Hematological Diagnostics and Genetics University Hospital in Krakow Krakow Poland $1 https://orcid.org/000000027428577X
700    1_
$a Czekalska, Sylwia $u Department of Hematological Diagnostics and Genetics University Hospital in Krakow Krakow Poland $1 https://orcid.org/0009000737367577
700    1_
$a Chatzidimitriou, Anastasia $u Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
700    1_
$a Laidou, Stamatia $u Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece $1 https://orcid.org/0000000246361579
700    1_
$a Bidet, Audrey $u Laboratoire d'Hématologie Biologique CHU Bordeaux Bordeaux France $1 https://orcid.org/0000000309928377
700    1_
$a Dussiau, Charles $u Laboratoire d'Hématologie Biologique CHU Bordeaux Bordeaux France
700    1_
$a Nollet, Friedel $u Department of Laboratory Medicine AZ Sint-Jan Hospital Bruges Belgium
700    1_
$a Piras, Giovanna $u Laboratorio specialistico UOC ematologia Ospedale San Francesco ASL Nuoro Italy
700    1_
$a Monne, Maria $u Laboratorio specialistico UOC ematologia Ospedale San Francesco ASL Nuoro Italy
700    1_
$a Smirnova, Svetlana $u National Medical Research Center for Hematology Moscow Russia $1 https://orcid.org/0000000162208868
700    1_
$a Nikitin, Eugene $u Outpatient department of Hematology, Oncology and Chemotherapy, Botkin Hospital, and Department of Hematology and Transfusiology Russian Medical Academy of Continuous Professional Education Moscow Russia $1 https://orcid.org/0000000224901263
700    1_
$a Sloma, Ivan $u Univ Paris Est Creteil, INSERM, IMRB Creteil France $u Departement d'Hematologie et Immunologie Biologique AP-HP, Hopital Henri Mondor Creteil France
700    1_
$a Claudel, Alexis $u Univ Paris Est Creteil, INSERM, IMRB Creteil France $u Departement d'Hematologie et Immunologie Biologique AP-HP, Hopital Henri Mondor Creteil France
700    1_
$a Largeaud, Laetitia $u Institut Universitaire de Cancérologie de Toulouse Toulouse France $1 https://orcid.org/0000000153415427
700    1_
$a Ysebaert, Loïc $u Institut Universitaire de Cancérologie de Toulouse Toulouse France $1 https://orcid.org/0000000341027261
700    1_
$a Valk, Peter J M $u Department of Hematology, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands $1 https://orcid.org/0000000288579461
700    1_
$a Christian, Amy $u Molecular Pathology University Hospitals Dorset Bournemouth UK
700    1_
$a Walewska, Renata $u Molecular Pathology University Hospitals Dorset Bournemouth UK
700    1_
$a Oscier, David $u Molecular Pathology University Hospitals Dorset Bournemouth UK
700    1_
$a Sebastião, Marta $u Laboratório Hemato-Oncologia Instituto Português de Oncologia de Lisboa Lisbon Portugal $1 https://orcid.org/0000000250701599
700    1_
$a da Silva, Maria Gomes $u Serviço de Hematologia Instituto Português de Oncologia de Lisboa Lisbon Portugal $1 https://orcid.org/0000000269932450
700    1_
$a Galieni, Piero $u UOC Hematology Mazzoni Hospital-Ascoli Piceno Ascoli Piceno Italy
700    1_
$a Angelini, Mario $u UOC Hematology Mazzoni Hospital-Ascoli Piceno Ascoli Piceno Italy
700    1_
$a Rossi, Davide $u Institute of Oncology Research and Oncology Institute of Southern Switzerland Bellinzona Switzerland
700    1_
$a Spina, Valeria $u Laboratorio di Diagnostica Molecolare, Servizio di Genetica Medica EOLAB Ente Ospedaliero Cantonale Bellinzona Switzerland
700    1_
$a Matos, Sónia $u Genomed-Diagnósticos de Medicina Molecular iMM - Instituto de Medicina Molecular, Faculdade de Medicina Lisboa Portugal
700    1_
$a Martins, Vânia $u Genomed-Diagnósticos de Medicina Molecular iMM - Instituto de Medicina Molecular, Faculdade de Medicina Lisboa Portugal
700    1_
$a Stokłosa, Tomasz $u Department of Tumor Biology and Genetics Medical University of Warsaw Warsaw Poland $1 https://orcid.org/0000000169185056
700    1_
$a Pepek, Monika $u Department of Tumor Biology and Genetics Medical University of Warsaw Warsaw Poland $1 https://orcid.org/0000000335068040
700    1_
$a Baliakas, Panagiotis $u Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden
700    1_
$a Andreu, Rafa $u Hematology Department Hospital Universitari i Politècnic la Fe Valencia Spain
700    1_
$a Luna, Irene $u Hematology Department Hospital Universitari i Politècnic la Fe Valencia Spain
700    1_
$a Kahre, Tiina $u Department of Laboratory Genetics, Genetics and Personalized Clinic Tartu University Hospital Tartu Estonia $u Genetics and Personalized Medicine Clinic, Institute of Clinical Medicine Tartu University Tartu Estonia $1 https://orcid.org/000900074399354X
700    1_
$a Murumets, Ülle $u Department of Laboratory Genetics, Genetics and Personalized Clinic Tartu University Hospital Tartu Estonia
700    1_
$a Pikousova, Tereza $u Centre for Molecular Medicine, Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic
700    1_
$a Kurucova, Terezia $u Centre for Molecular Medicine, Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic $1 https://orcid.org/0009000871105543
700    1_
$a Laird, Sophie $u Wessex Genomics Laboratory Service Salisbury NHS Foundation Trust Salisbury UK
700    1_
$a Ward, Daniel $u Wessex Genomics Laboratory Service Salisbury NHS Foundation Trust Salisbury UK
700    1_
$a Alcoceba, Miguel $u Department of Hematology University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Center of Salamanca-IBMCC (USAL-CSIC) Salamanca Spain $1 https://orcid.org/0000000238194846
700    1_
$a Balanzategui, Ana $u Department of Hematology University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Center of Salamanca-IBMCC (USAL-CSIC) Salamanca Spain $1 https://orcid.org/0000000306608183
700    1_
$a Scarfo, Lydia $u B-Cell Neoplasia Unit and Strategic Research Program on CLL IRCCS Ospedale San Raffaele Milan Italy $u Medical School Università Vita-Salute San Raffaele Milan Italy
700    1_
$a Gandini, Francesca $u B-Cell Neoplasia Unit and Strategic Research Program on CLL IRCCS Ospedale San Raffaele Milan Italy $u Medical School Università Vita-Salute San Raffaele Milan Italy
700    1_
$a Zapparoli, Ettore $u Center for Omics Sciences IRCCS Ospedale San Raffaele Milan Italy $1 https://orcid.org/0000000341707902
700    1_
$a Blanco, Adoración $u Department of Hematology Hospital Universitari Vall d'Hebron (HUVH) Barcelona Spain $u Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain $u Department of Medicine Universitat Autònoma de Barcelona (UAB) Barcelona Spain
700    1_
$a Abrisqueta, Pau $u Department of Hematology Hospital Universitari Vall d'Hebron (HUVH) Barcelona Spain $u Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain $u Department of Medicine Universitat Autònoma de Barcelona (UAB) Barcelona Spain
700    1_
$a Rodríguez-Vicente, Ana E $u Oncohematology Research Group, Institute of Biomedical Research of Salamanca (IBSAL) Cancer Research Centre (IBMCC, USAL-CSIC) and University of Salamanca Salamanca Spain $u Department of Human Anatomy and Histology, Faculty of Medicine University of Salamanca Salamanca Spain $1 https://orcid.org/0000000165162172
700    1_
$a Benito, Rocío $u Oncohematology Research Group, Institute of Biomedical Research of Salamanca (IBSAL) Cancer Research Centre (IBMCC, USAL-CSIC) and University of Salamanca Salamanca Spain $1 https://orcid.org/0000000197814198
700    1_
$a Bravetti, Clotilde $u Department of Biological Hematology Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital Paris France
700    1_
$a Davi, Frédéric $u Department of Biological Hematology Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital Paris France
700    1_
$a Gameiro, Paula $u Laboratório Hemato-Oncologia Instituto Português de Oncologia de Lisboa Lisbon Portugal $1 https://orcid.org/0000000237617050
700    1_
$a Martinez-Lopez, Joaquin $u Department of Hematology Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Complutense University, CNIO, CIBERONC Madrid Spain
700    1_
$a Tazón-Vega, Bárbara $u Department of Hematology Hospital Universitari Vall d'Hebron (HUVH) Barcelona Spain $u Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain $u Department of Medicine Universitat Autònoma de Barcelona (UAB) Barcelona Spain
700    1_
$a Baran-Marszak, Fanny $u Hematology laboratory HUPSSD, Hôpital Avicenne, APHP Bobigny France $u INSERM U978 Université Sorbonne Paris Nord Bobigny France
700    1_
$a Davis, Zadie $u Molecular Pathology University Hospitals Dorset Bournemouth UK
700    1_
$a Catherwood, Mark $u Haematology Department Belfast City Hospital Belfast UK
700    1_
$a Sudarikov, Andrey $u National Medical Research Center for Hematology Moscow Russia $1 https://orcid.org/0000000194639187
700    1_
$a Rosenquist, Richard $u Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden $u Department of Clinical Genetics and Genomics Karolinska University Hospital Stockholm Sweden $1 https://orcid.org/0000000202118788
700    1_
$a Niemann, Carsten U $u Department of Hematology Copenhagen University Hospital - Rigshospitalet Copenhagen Denmark
700    1_
$a Stamatopoulos, Kostas $u Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
700    1_
$a Ghia, Paolo $u B-Cell Neoplasia Unit and Strategic Research Program on CLL IRCCS Ospedale San Raffaele Milan Italy $u Medical School Università Vita-Salute San Raffaele Milan Italy $1 https://orcid.org/0000000337507342 $7 xx0314871
700    1_
$a Pospisilova, Sarka $u Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic $u Centre for Molecular Medicine, Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic $1 https://orcid.org/0000000171362680 $7 xx0101843
773    0_
$w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 9, č. 1 (2025), s. e70065
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39840379 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095737 $b ABA008
999    __
$a ok $b bmc $g 2306437 $s 1245686
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 9 $c 1 $d e70065 $e 20250120 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
LZP    __
$a Pubmed-20250408

Najít záznam

Citační ukazatele

Možnosti archivace